Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/328490
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampOliveira, Mariana Gonçalves dept_BR
dc.contributor.authorunicampCalmasini, Fabiano Beraldipt_BR
dc.contributor.authorunicampAlexandre, Eduardo Costapt_BR
dc.contributor.authorunicampDe Nucci, Gilbertopt_BR
dc.contributor.authorunicampMónica, Fabíola Zakia Tauficpt_BR
dc.contributor.authorunicampAntunes, Edsonpt_BR
dc.typeArtigopt_BR
dc.titleActivation Of Soluble Guanylyl Cyclase By Bay 58-2667 Improves Bladder Function In Cyclophosphamide-induced Cystitis In Miceen
dc.titleActivation of soluble guanylyl cyclase by bay 58-2667 improves bladder function in cyclophosphamide-induced cystitis in micept_BR
dc.contributor.authorOliveira, Mariana G. dept_BR
dc.contributor.authorCalmasini, Fabiano B.pt_BR
dc.contributor.authorAlexandre, Eduardo C.pt_BR
dc.contributor.authorDe Nucci, Gilbertopt_BR
dc.contributor.authorMonica, Fabiola Z.pt_BR
dc.contributor.authorAntunes, Edson Fabiano B.pt_BR
dc.contributor.authorAlexandre Eduardo C.pt_BR
dc.contributor.authorDe Nucci Gilbertopt_BR
dc.contributor.authorMonica Fabiola Z.pt_BR
dc.contributor.authorAntunes Edsonpt_BR
dc.subjectUrinary Bladderen
dc.subjectCystometryen
dc.subjectBladder Pain Syndromeen
dc.subjectCgmpen
dc.subjectBexigapt_BR
dc.subject.otherlanguageBladderpt_BR
dc.description.abstractActivators of soluble guanylyl cyclase (sGC) interact directly with its prosthetic heme group, enhancing the enzyme responsiveness in pathological conditions. This study aimed to evaluate the effects of the sGC activator BAY 58-2667 on voiding dysfunction, protein expressions of alpha(1) and beta 1 sGC subunits and cGMP levels in the bladder tissues after cyclophosphamide (CYP) exposure. Female C57BL/6 mice (20-25 g) were injected with CYP (300 mg/kg ip) to induce cystitis. Mice were pretreated or not with BAY 58-2667 (1 mg/kg, gavage), given 1 h before CYP injection. The micturition patterns and in vitro bladder contractions were evaluated at 24 h. In freely moving mice, the CYP injection produced reduced the micturition volume and increased the number of urine spots. Cystometric recordings in CYP-injected mice revealed significant increases in basal pressure, voiding frequency, and nonvoiding contractions (NVCs), along with decreases in bladder capacity, intercontraction interval, and compliance. BAY 58-2667 significantly prevented the micturition alterations observed in both freely moving mice and cystometry and normalized the reduced in vitro carbachol-induced contractions in the CYP group. Reduced protein expressions of alpha(1) and beta(1) sGC subunits and of cGMP levels were observed in the CYP group, all of which were prevented by BAY 58-2667. CYP exposure significantly increased reactive-oxygen species (ROS) generation in both detrusor and urothelium, and this was normalized by BAY 58-2667. The increased myeloperoxidase and cyclooxygenase-2 activities in the bladders of the CYP group remained unchanged by BAY 58-2667. Activators of sGC may constitute a novel and promising therapeutic approach for management of interstitial cystitis.en
dc.description.abstractActivators of soluble guanylyl cyclase (sGC) interact directly with its prosthetic heme group, enhancing the enzyme responsiveness in pathological conditions. This study aimed to evaluate the effects of the sGC activator BAY 58-2667 on voiding dysfunction, protein expressions of alpha(1) and beta 1 sGC subunits and cGMP levels in the bladder tissues after cyclophosphamide (CYP) exposure. Female C57BL/6 mice (20-25 g) were injected with CYP (300 mg/kg ip) to induce cystitis. Mice were pretreated or not with BAY 58-2667 (1 mg/kg, gavage), given 1 h before CYP injection. The micturition patterns and in vitro bladder contractions were evaluated at 24 h. In freely moving mice, the CYP injection produced reduced the micturition volume and increased the number of urine spots. Cystometric recordings in CYP-injected mice revealed significant increases in basal pressure, voiding frequency, and nonvoiding contractions (NVCs), along with decreases in bladder capacity, intercontraction interval, and compliance. BAY 58-2667 significantly prevented the micturition alterations observed in both freely moving mice and cystometry and normalized the reduced in vitro carbachol-induced contractions in the CYP group. Reduced protein expressions of alpha(1) and beta(1) sGC subunits and of cGMP levels were observed in the CYP group, all of which were prevented by BAY 58-2667. CYP exposure significantly increased reactive-oxygen species (ROS) generation in both detrusor and urothelium, and this was normalized by BAY 58-2667. The increased myeloperoxidase and cyclooxygenase-2 activities in the bladders of the CYP group remained unchanged by BAY 58-2667. Activators of sGC may constitute a novel and promising therapeutic approach for management of interstitial cystitispt
dc.relation.ispartofAmerican journal of physiology: renal physiologypt_BR
dc.relation.ispartofabbreviationAm j physiol renal physiolpt_BR
dc.publisher.cityRockville, MDpt_BR
dc.publisher.countryEstados Unidospt_BR
dc.publisherAmerican Physiological Societypt_BR
dc.date.issued2016pt_BR
dc.date.monthofcirculationJulypt_BR
dc.identifier.citationAmerican Journal Of Physiology-renal Physiology. Amer Physiological Soc, v. 311, p. F85 - F93, 2016.pt_BR
dc.language.isoengpt_BR
dc.description.volume311pt_BR
dc.description.issuenumber1pt_BR
dc.description.firstpageF85pt_BR
dc.description.lastpageF93pt_BR
dc.rightsfechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn1931-857Xpt_BR
dc.identifier.eissn1522-1466pt_BR
dc.identifier.doi10.1152/ajprenal.00041.2016pt_BR
dc.identifier.urlhttp://ajprenal.physiology.org/content/311/1/F85pt_BR
dc.description.sponsorshipFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOpt_BR
dc.description.sponsorshipCNPQ – CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOpt_BR
dc.description.sponsorship1FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOpt_BR
dc.description.sponsorship1CNPQ – CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOpt_BR
dc.description.sponsordocumentnumbersem informaçãopt_BR
dc.description.sponsordocumentnumbersem informaçãopt_BR
dc.date.available2017-11-13T13:25:25Z-
dc.date.accessioned2017-11-13T13:25:25Z-
dc.description.provenanceMade available in DSpace on 2017-11-13T13:25:25Z (GMT). No. of bitstreams: 1 000380826900013.pdf: 3235485 bytes, checksum: 218639484380d6465494066a1a0a89de (MD5) Previous issue date: 2016 Bitstreams deleted on 2020-05-18T20:41:41Z: 000380826900013.pdf,. Added 1 bitstream(s) on 2020-05-19T14:31:50Z : No. of bitstreams: 1 000380826900013.pdf: 3314564 bytes, checksum: 9a620474848b085fce7243eadf27b7ce (MD5)en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/328490-
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.identifier.source000380826900013-
dc.creator.orcidsem informaçãopt_BR
dc.creator.orcidsem informaçãopt_BR
dc.creator.orcid0000-0002-9482-6799pt_BR
dc.creator.orcid0000-0002-4346-7941pt_BR
dc.creator.orcid0000-0002-8449-6677pt_BR
dc.creator.orcid0000-0003-2201-8247pt_BR
dc.type.formArtigo originalpt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000380826900013.pdf3.24 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.